Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 4/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.63 |
| ▸ | MAPT | P10636 | 4/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.63 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.63 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | THRB | P10828 | 1/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.54 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.54 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.54 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.54 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.54 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14279021 | 0.87 | OPRM1 (0.71) | OPRM1SMN1; SMN2MAPTALDH1A1LMNA | |
| SCHEMBL4873297 | 0.87 | OPRM1 (0.74) | OPRM1CHRM2CHRM1SLC22A1SLC6A4 | |
| SCHEMBL3990760 | 0.86 | OPRM1 (0.57) | OPRM1SLC22A1SLC6A4ADRA1AOPRD1 | |
| SCHEMBL28305036 | 0.84 | OPRM1 (0.56) | OPRM1SLC22A1SLC6A4ADRA1AOPRD1 | |
| SCHEMBL21874377 | 0.84 | OPRM1 (0.72) | OPRM1SLC22A1SLC6A4ADRA1AOPRD1 | |
| SCHEMBL24608752 | 0.84 | OPRM1 (0.64) | OPRM1SMN1; SMN2MAPTALDH1A1CHRM2 | |
| SCHEMBL5860380 | 0.84 | OPRM1 (0.64) | OPRM1SMN1; SMN2MAPTALDH1A1CHRM2 | |
| SCHEMBL343848 | 0.84 | OPRM1 (0.56) | OPRM1CHRM2CHRM1SLC22A1SLC6A4 | |
| SCHEMBL6660823 | 0.84 | OPRM1 (0.75) | OPRM1ALDH1A1CHRM2CHRM1LMNA | |
| SCHEMBL23225664 | 0.83 | OPRM1 (0.73) | OPRM1ALDH1A1CHRM2CHRM1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2004039409-A2 | COMPOSITION COMPRISING ACTIVATORS OF IK POTASSIUM CHANNELS AND CALCINEURIN ANTAGONISTS AND USE THEREOF | SWITCH BIOTECH AG (DE) | 2004-05-13 | — | — | WO | claimed |
| US-20020169203-A1 | Ion channel modulating agents | NEUROSEARCH A/S (DK) | 2002-11-14 | — | — | US | claimed |
| EP-1140784-A2 | ION CHANNEL MODULATING AGENTS | NEUROSEARCH A/S (DK) | 2001-10-10 | — | — | EP | claimed |
| WO-2000037422-A2 | ION CHANNEL MODULATING AGENTS | NEUROSEARCH A/S (DK) | 2000-06-29 | — | — | WO | claimed |
| US-7012146-B2 | Ion channel modulating agents | POSEIDON PHARMACEUTICALS A/S (DK) | 2006-03-14 | — | — | US | disclosed |
| EP-1345618-B1 | CHLORZOXAZONE FOR THE TREATMENT OF PSORIASIS | SWITCH BIOTECH AG (DE) | 2005-03-23 | — | — | EP | disclosed |
| US-20040248099-A1 | Use of intermediate -conductance potassium channels and modulators for diagnosing and treating diseases having disturbed keratinocyte activity | SWITCH BIOTECH AKTIENGESELLSCHAFT (DE) | 2004-12-09 | — | — | US | disclosed |
| WO-2004039409-A2 | COMPOSITION COMPRISING ACTIVATORS OF IK POTASSIUM CHANNELS AND CALCINEURIN ANTAGONISTS AND USE THEREOF | SWITCH BIOTECH AG (DE) | 2004-05-13 | — | — | WO | disclosed |
| EP-1345618-A2 | USE OF INTERMEDIATE-CONDUCTANCE POTASSIUM CHANNELS AND MODULATORS FOR THE DIAGNOSIS AND TREATMENT OF ILLNESSES HAVING DISTURBED KERATINOCYTE ACTIVITY | Switch Biotech Aktiengesellschaft (DE) | 2003-09-24 | — | — | EP | disclosed |
| US-20020169203-A1 | Ion channel modulating agents | NEUROSEARCH A/S (DK) | 2002-11-14 | — | — | US | disclosed |
| WO-2002053171-A2 | USE OF INTERMEDIATE-CONDUCTANCE POTASSIUM CHANNELS AND MODULATORS FOR THE DIAGNOSIS AND TREATMENT OF ILLNESSES HAVING DISTURBED KERATINOCYTE ACTIVITY | SWITCH BIOTECH AKTIENGESELLSCHAFT (DE) | 2002-07-11 | — | — | WO | disclosed |
| EP-1140784-A2 | ION CHANNEL MODULATING AGENTS | NEUROSEARCH A/S (DK) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000037422-A2 | ION CHANNEL MODULATING AGENTS | NEUROSEARCH A/S (DK) | 2000-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020169203-A1 | Ion channel modulating agents | KCNN3, KCNN1, KCNN2 | OPRM1 2346/4885SMN1; SMN2 2391/4885MAPT 2674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.